AXT, Inc. (AXTI) Misses Q4 EPS by 1c; Issues Q1 EPS, Revs Outlook
Tweet
Share
E-mailGet Alerts AXTI Hot Sheet
Price: $61.64 --0%
EPS Growth %: +433.3%
Financial Fact:
Diluted (in dollars per share): 0.07
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +433.3%
Financial Fact:
Diluted (in dollars per share): 0.07
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
AXT, Inc. (NASDAQ: AXTI) reported Q4 EPS of $0.08, $0.01 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $21.2 million versus the consensus estimate of $21.34 million.
AXT, Inc. sees Q1 2012 EPS of $0.07-$0.11, versus the consensus of $0.08. AXT, Inc. sees Q1 2012 revenue of $21-$24 million, versus the consensus of $20.54 million.
For earnings history and earnings-related data on AXT, Inc. (AXTI) click here.
AXT, Inc. sees Q1 2012 EPS of $0.07-$0.11, versus the consensus of $0.08. AXT, Inc. sees Q1 2012 revenue of $21-$24 million, versus the consensus of $20.54 million.
For earnings history and earnings-related data on AXT, Inc. (AXTI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Akari Therapeutics to present ADC platform at five September conferences
- Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
